Investing Profile

Chris Garabedian


CEO, Xontogeny and Portfolio Manager, PXV Fund, Massachusetts
Photo of Chris Garabedian, Investor at Perceptive Advisors

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Perceptive Advisors Investor
$100K - $10.0M
CompanyStageDateRound SizeTotal Raised
Nephraegis Therapeutics
Seed RoundMay 2021
Shifa Biomedical
Seed RoundMay 2021
Peroxitech Therapeutics
Seed RoundMay 2021
Tellus Therapeutics
Seed RoundMay 2021$2M
Juno Diagnostics
Series AMay 2021$25M
Forge Biologics
Series BApr 2021$120M
Series AJul 2020$40M
AsclepiX Therapeutics
Series AJun 2020$35M
Co-investors: Kevin Slawin (Rapha Capital Management)
Series AJun 2020$44M